Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,404.00
Bid: 12,404.00
Ask: 12,408.00
Change: -24.00 (-0.19%)
Spread: 4.00 (0.032%)
Open: 12,474.00
High: 12,480.00
Low: 12,402.00
Prev. Close: 12,428.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Infections Drop As study Backs Long AstraZeneca Jab Dose Interval

Fri, 19th Feb 2021 16:44

(Alliance News) - Coronavirus infections are dropping across the UK, new data suggests, as a study found that giving doses of the Oxford/AstraZeneca PLC vaccine 12 weeks apart improves protection.

Around one in 115 people in private households in England had Covid-19 between February 6 and 12, the Office for National Statistics (ONS) said, down from around one in 80 people from January 31 to February 6.

Meanwhile, in Wales, around one in 125 people are estimated to have had Covid-19 between February 6 and 12, down from one in 85 previously.

In Northern Ireland, the figure is around one in 105 people, down from one in 75, while in Scotland it is around one in 180 people, down from one in 150.

The data, which does not cover care homes and hospitals, is based on swab tests from thousands of people regardless of whether or not they have symptoms.

It comes as new analysis from Oxford University published in The Lancet confirmed that a single dose of the AstraZeneca vaccine offers 76% protection against Covid-19 from 22 days after vaccination, and that this had not waned by the three-month mark.

The UK policy of leaving up to 12 weeks between doses also resulted in a higher efficacy overall, the study found.

There was 81% protection when three months was left between the two doses, compared to 55% for up to a six-week interval.

The Oxford team is still urging people to have two doses of the vaccine because they say it is not yet clear how long protection with a single dose may last.

Meanwhile, government scientists put the R – the number of people an infected person will pass coronavirus on to – at 0.6 to 0.9 for the UK, compared to 0.7 to 0.9 in the previous week.

The lower end estimate is at its lowest point recorded by the scientists, and the R is below 1 in all regions of England.

However, the experts warned that "prevalence of the virus remains high, so it remains vital that everyone continues to stay at home in order to keep the R value down".

Earlier, top scientific advisers said vaccines were having an impact on the pandemic, as Prime Minister Boris Johnson prepares to publish his road map out of lockdown on Monday.

Professor Adam Finn, from the University of Bristol and a member of the Joint Committee on Vaccination and Immunisation (JCVI), said "everything's moving in the right direction" when it comes to how jabs are working.

He told BBC Radio 4's Today programme: "We've now got to the point with the study we're doing in Bristol where we can say with certainty that there is definitely an effect.

"It's just hard to put an exact number on it at this point because… the numbers of cases coming through are still building up, the number of people who've been vaccinated are still going up, but it's becoming clearer for the Pfizer Inc vaccine, which we've been using for a month longer, since early December, and it'll take slightly longer for us to get a firm handle on just how well the AstraZeneca vaccine is preventing hospitalisations too, but they're definitely doing the job."

Professor Neil Ferguson, from Imperial College London, said the data on vaccine effectiveness and how quickly infection, deaths and hospital cases were declining across the country was looking promising.

He said he thought the current lockdown should be lifted in stages, adding: "I am encouraged by the cautious approach being taken, an incremental approach which I think will be adopted, namely relax one thing and see what the impact is, relax again.

"And it still may well be that by the end of May, we're in a very different country than we are today."

Figures show a continued decline since Christmas in the number of new cases of coronavirus, although rates vary according to region.

Overall, 74,961 new cases were recorded in England in the seven days to February 14, the equivalent of 133.2 per 100,000 people.

This is down sharply from a peak of 680.8 cases per 100,000 people on January 4.

It is also the lowest seven-day rate since October 4.

Meanwhile, the number of patients in hospital in England with Covid-19 has also fallen sharply in recent weeks.

A total of 15,633 patients were in hospital as of 8am on February 18, down 54% from a record 34,336 patients exactly one month earlier.

But while this is a sizeable drop, numbers at both a national and regional level are still higher than when England came out of its second lockdown on December 2.

All regions also continue to report patient numbers well above those seen last May, when Boris Johnson announced the initial easing of the first lockdown.

Meanwhile the number of daily hospital admissions of patients with Covid-19 stood at 1,311 on February 16, down 68% from a peak of 4,134 on January 12, but still above the 1,262 on the day England came out of its second lockdown on December 2.

Elsewhere, Wales' First Minister Mark Drakeford has said some aspects of non-essential retail, as well as personal services such as hairdressing, could begin to reopen there from March 15, with stay-at-home restrictions eased in three weeks.

All primary school children in Wales are expected to return to face-to-face teaching from mid-March, while the number of people allowed to exercise together will increase from two to four.

source: PA

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more
27 Dec 2023 17:04

Rate-cut optimism, autos push UK stocks higher

FTSE 100 up 0.4%, FTSE 250 adds 0.5%

*

Read more
27 Dec 2023 17:02

LONDON MARKET CLOSE: Stocks start week higher as 2024 draws to close

(Alliance News) - Equities in London kicked off an abbreviated trading week with gains on Wednesday, on continued US interest rate optimism at the end of 2024.

Read more
27 Dec 2023 14:25

London close: Stocks maintain gains amid post-Christmas rally

(Sharecast News) - London's stock markets closed in positive territory on Wednesday, buoyed by a global surge in stock prices as the S&P 500 neared an all-time high on Wall Street.

Read more
27 Dec 2023 12:06

LONDON MARKET MIDDAY: Stocks hold onto gains amid US rate cut hopes

(Alliance News) - London's FTSE 100 index was outperforming other European stock-price measures at midday on Wednesday, boosted by gains for miners and industrials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.